Welcome to our dedicated page for Milestone Pharmaceuticals SEC filings (Ticker: MIST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Milestone Pharmaceuticals Inc. (MIST) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding how Milestone reports on its cardiovascular drug programs, financial position, and material corporate events.
For Milestone, current reports on Form 8-K are especially important. Recent 8-K filings describe key milestones such as U.S. Food and Drug Administration approval of CARDAMYST™ (etripamil) nasal spray for adult paroxysmal supraventricular tachycardia (PSVT), acceptance of the company’s response to a Complete Response Letter, new PDUFA target dates, equity offerings, amendments to royalty purchase agreements, and the filing or use of corporate presentations. These filings often incorporate press releases that discuss clinical data, regulatory status, and financing terms in more detail.
Investors can also use this page to locate periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which Milestone references in its news releases. Those documents typically include audited or reviewed financial statements, discussions of research and development and commercial expenses, and risk factor sections addressing uncertainties around regulatory approvals, clinical trials, capital resources, and market conditions.
In addition, Milestone’s capital-raising activities are documented through registration statements and related filings, along with 8-Ks that summarize underwriting agreements, warrant terms, and senior secured convertible notes. These materials explain how the company finances the development and commercialization of CARDAMYST and the broader etripamil program.
On Stock Titan, users can view these filings as they are made available from EDGAR and rely on AI-powered summaries to highlight the main points in lengthy documents, including 10-Ks, 10-Qs, and 8-Ks. The platform also makes it easier to identify items related to topics such as regulatory approvals, financing transactions, and updates on the PSVT and AFib-RVR programs, helping readers navigate Milestone’s disclosure record more efficiently.
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) has launched a high-dilution capital raise via a Rule 424(b)(5) prospectus supplement. The company is offering 31,500,000 common shares and, for investors that elect, 3,502,335 pre-funded warrants, each unit paired with one Series A and one Series B common warrant. The combined public offering price is $1.50 per common share unit and $1.499 per pre-funded warrant unit, implying only a modest 3.8 % discount to the prior $1.56 closing price (11 July 2025).
The package delivers:
- Gross proceeds: $52.5 million
- Underwriting fees: $3.15 million (6.0%)
- Estimated net proceeds: ≈ $48.7 million after offering expenses
- New share count: 84,964,273 basic shares post-offering (up 59%)
Warrants provide additional leverage. Series A warrants (exercise $1.50) expire in one year; Series B warrants (exercise $1.875) run five years and include a forced-exercise feature once the stock trades ≥ $3.50 for 10 consecutive days. If fully exercised for cash, the warrants could yield a further $118.1 million.
Use of proceeds. Management will direct funds to commercial readiness and continued clinical development of etripamil (CARDAMYST), its intranasal calcium-channel blocker for paroxysmal supraventricular tachycardia (PSVT) and AFib-RVR, plus general corporate purposes. Cash, equivalents and short-term investments were $56.0 million at 31 Mar 2025 and a preliminary $43.4 million at 30 Jun 2025; the raise extends liquidity into 2026.
Regulatory status. The FDA issued a Complete Response Letter in March 2025, citing CMC issues. Milestone submitted a response that was accepted 11 Jul 2025, setting a new PDUFA action date of 13 Dec 2025. Approval before 31 Dec 2025 would also trigger a $75 million royalty monetisation from RTW Investments (deadline recently extended).
Dilution & capital structure. The offering increases outstanding shares by ~31.5 million (plus up to 35 million additional warrant shares), on top of 53.5 million existing. Outstanding options (7.8 million), legacy pre-funded warrants (12.9 million) and convertible notes (up to 15.7 million shares) add further potential dilution. Pro-forma tangible book value turns positive at $0.47/sh, but immediate dilution to new buyers is $1.03/sh.
Key risks. The raise is contingent on no guarantees of FDA approval; warrants create overhang; absence of warrant listing limits liquidity; the company remains pre-revenue and subject to clinical, regulatory and execution risks detailed under “Risk Factors”.
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) filed an 8-K on 10 July 2025 disclosing two material events:
- Royalty Purchase Agreement Amendment (Item 1.01): The Company and RTW Royalty I DAC agreed to extend the Marketing Approval Deadline for etripamil from 30 Sep 2025 to 31 Dec 2025. The amendment provides Milestone with an additional three months to secure U.S. marketing approval before contractual milestone or repayment provisions are triggered. Full terms will be included in the next periodic filing.
- Regulatory Update (Item 8.01): On 11 July 2025 the FDA accepted Milestone’s complete response to the prior Complete Response Letter for its New Drug Application (NDA) for CARDAMYST (etripamil) nasal spray targeting paroxysmal supraventricular tachycardia. The agency set a new Prescription Drug User Fee Act (PDUFA) action date of 13 Dec 2025.
Investment view: FDA acceptance and a defined PDUFA date re-start the approval clock, reducing regulatory uncertainty and acting as an upside catalyst. The three-month extension in the royalty agreement aligns contractual timelines with the new PDUFA date, avoiding potential covenant breaches. No financial statements were included, but successful approval would unlock royalty financing and potential commercialization revenue.